|
SBIR and STTR Success Story for LigoCyte Pharmaceuticals (Information Posted/Updated on 08/10/2007) |
|
|
|
|
|
LigoCyte Pharmaceuticals 2155 Analysis Drive Bozeman, MT 59718-6831 Contact: Robert F. Bargatze, Ph.D. Phone: 406-585-2733 Fax: 406-585-2766 E-mail: robert.bargatze@ligocyte.com Web Site: http://www.ligocyte.com |
|
|
Project Title: Rational Design of Adhesion Blocking Anti-Inflammatories |
|
| Related Award(s): R44 A143789-04; 5RR44 AI43789-6 | |
|
Technology Developed:
LigoCyte has developed a monoclonal antibody capable of inhibiting inflammatory disease in the lung.
|
|
| Key Words: chronic inflammation, antibody, adhesion, pulmonary. | |
|
Uses of Technology/Products/Service:
This technology is a therapeutic drug to treat chronic inflammatory disease.
|
|
|
Benefit to Company:
The SBIR program has had a profound impact on the ability of the company to develop this technology. Using data generated through research performed under the grant, LigoCyte was able to secure a pharmaceutical partner for the technology who is supporting further development, human clinical testing, manufacturing and product sales.
|
|
|
How Product Was Commercialized:
In continuing partner discussions.
|
|
|
Other Comments Related to Company's Success Story:
Human therapeutic mAb candidates generated and in preclinical development.
|
|
|
|
|